The company, part of the ChemRar group, specializes in developing drugs based on recombinant proteins and small molecules. They are also involved in the production of first generics and biosimilars. In 2016, BioIntegrator launched Neskler, the first generic version of fingolimod, a treatment for multiple sclerosis. The company utilizes transfer technology in its manufacturing process.